Letter to the Editor

Dramatic Response to Uracil-Tegafur (UFT) in an Elderly Patient with Nonsmall Cell Lung Cancer

Authors: Nobuhiro Kanaji, MD, PhD, Shuji Bandoh, MD, PhD, Toshihiko Ishida, MD, PhD

Abstract

To the Editor:


Uracil-tegafur (UFT) is an oral 5-fluorouracil derivative drug. However, few reports have demonstrated anti-tumor effects of UFT in patients with advanced nonsmall cell lung cancer (NSCLC), especially elderly patients with poor performance status. Here, we describe a case of an elderly patient with NSCLC whose tumor dramatically regressed following oral UFT.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Shimizu E, Kimura K, Sone S, et al. [A phase II study of UFT in non-small cell lung cancer] Gan To Kagaku Ryoho 1986;13:2970–2973.
 
2. Keicho N, Saijo N, Shinkai T, et al. Phase II study of UFT in patients with advanced non-small cell lung cancer. Jpn J Clin Oncol 1986;16:143–146.
 
3. Kato H, Ichinose Y, Ohta M, et al; Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004;350:1713–1721.
 
4. Schmoll HJ. Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: utility in the treatment of advanced colorectal cancer. Anticancer Drugs 2003;14:695–702.